心瑋醫療盤中高漲超9% 中期營收同比大增1287.4%
格隆匯9月2日丨心瑋醫療(6609.HK)今天盤中一度高漲9.23%至142港元,總市值約55億港元。心瑋醫療8月30日公佈中期業績,上半年實現營收3012.5萬元人民幣,同比增長1287.4%;毛利1905.2萬元,同比增長1641.5%。公司上半年的研發成本為3239萬元,對比2020年同期的1061萬元上漲超2倍。心瑋醫療表示,研發成本增加主要原因是心瑋在瞄準神經介入醫療在研器械產生的成本增加。在神經介入這類高端醫療器械行業的競爭中,產品研發效率是企業領先的關鍵。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.